Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | September 15, 2026 | September 15, 2026 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Finance CFO | February 02, 2024 | February 06, 2024 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,184 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 1,000 · Balance 8,184 |
REGENERON PHARMACEUTICALS, INC.
Report date February 02, 2024 · Filed February 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,693 |
Ending reported balance
After 2024-02-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-02 · Exercise / conversion · Acquired 400 · Balance 23,974 Row 2 · 2024-02-02 · Tax withholding · Disposed 281 · Balance 23,693 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $378.98 · Expires 2027-12-12 | Direct | 11,787 |
Reported balance
After 2024-02-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-02 · Exercise / conversion · Disposed 400 · Balance 11,787 F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 270 |
Reported balance
Holding disclosure · report date 2024-02-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 270 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $665.44 | $11,977.92 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 12 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,471 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 18 shares of Company stock on December 10, 2021 at prices ranging from $665.20 to $665.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 15 | $664.71 | $9,970.65 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 11 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,489 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19 | $663.41 | $12,604.79 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 10 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,504 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 19 shares of Company stock on December 10, 2021 at prices ranging from $663.16 to $663.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 123 | $662.06 | $81,433.38 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 9 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,523 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 123 shares of Company stock on December 10, 2021 at prices ranging from $662.06 to $662.17. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 25 | $661.48 | $16,537.00 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 8 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,646 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 25 shares of Company stock on December 10, 2021 at prices ranging from $661.26 to $661.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $659.49 | $2,637.96 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,671 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on December 10, 2021 at prices ranging from $659.36 to $659.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $658.52 | $7,243.72 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,675 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 11 shares of Company stock on December 10, 2021 at prices ranging from $658.10 to $658.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 50 | $657.53 | $32,876.50 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,686 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 50 shares of Company stock on December 10, 2021 at prices ranging from $657.19 to $657.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $656.46 | $1,312.92 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,736 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001883850-21-000028 · edgardoc.xml · derivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 1,500 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,384 | $664.34 | $919,446.56 |
DisclosureSEC source: 0001883850-21-000028 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,073 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,500 | $555.67 | $833,505.00 |
DisclosureSEC source: 0001883850-21-000028 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,250 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · derivative · entry 21 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 4,250 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 3,469 | $657.11 | $2,279,514.59 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,738 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,250 | $399.66 | $1,698,555.00 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,958 | $0.00 Strike: $644.54 | $0.00 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · derivative · entry 22 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,958 Underlying: Common Stock · 16,958 shares Expires 2031-12-08 F15 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000096 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,957 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2023 and 50% on December 8, 2025. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 681 | $645.08 | $439,299.48 |
DisclosureSEC source: 0001708138-21-000088 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,986 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001708138-21-000088 · edgardoc.xml · derivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 3,750 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 3,069 | $651.97 | $2,000,895.93 |
DisclosureSEC source: 0001708138-21-000088 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,667 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,750 | $399.66 | $1,498,725.00 |
DisclosureSEC source: 0001708138-21-000088 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001708138-21-000070 · edgardoc.xml · derivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 1,000 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 917 | $675.03 | $619,002.51 |
DisclosureSEC source: 0001708138-21-000070 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,986 Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $555.67 | $555,670.00 |
DisclosureSEC source: 0001708138-21-000070 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $619.19 | $4,334.33 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 20 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,903 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on August 10, 2021 at prices ranging from $619.16 to $619.24. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 45 | $618.89 | $27,850.05 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 19 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,910 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 45 shares of Company stock on August 10, 2021 at prices ranging from $618.13 to $618.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $615.73 | $615.73 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 18 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,955 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $614.09 | $614.09 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 17 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,956 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 50 | $612.31 | $30,615.50 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 16 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,957 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 433 | $611.00 | $264,563.00 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 15 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,007 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · derivative · entry 23 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,565 Underlying: Common Stock · 3,000 shares Expires 2026-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,463 | $617.68 | $1,521,345.84 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 14 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,440 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,000 | $381.92 | $1,145,760.00 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 13 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 36 | $623.54 | $22,447.44 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 12 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,903 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 36 shares of Company stock on August 9, 2021 at prices ranging from $623.40 to $623.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 9, 2021 at each separate price. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 54 | $621.19 | $33,544.26 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 11 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,939 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 54 shares of Company stock on August 9, 2021 at prices ranging from $621.02 to $621.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 9, 2021 at each separate price. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 36 | $619.70 | $22,309.20 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 10 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,993 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 36 shares of Company stock on August 9, 2021 at prices ranging from $619.48 to $619.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 9, 2021 at each separate price. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 58 | $618.44 | $35,869.52 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 9 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,029 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 58 shares of Company stock on August 9, 2021 at prices ranging from $618.14 to $618.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 9, 2021 at each separate price. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 36 | $617.83 | $22,241.88 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 8 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,087 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 36 shares of Company stock on August 9, 2021 at prices ranging from $617.73 to $617.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 9, 2021 at each separate price. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 40 | $615.42 | $24,616.80 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,123 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 40 shares of Company stock on August 9, 2021 at prices ranging from $615.35 to $615.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 9, 2021 at each separate price. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 66 | $614.70 | $40,570.20 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,163 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 66 shares of Company stock on August 9, 2021 at prices ranging from $614.34 to $614.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 9, 2021 at each separate price. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $613.79 | $613.79 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,229 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 36 | $612.97 | $22,066.92 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,230 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 36 shares of Company stock on August 9, 2021 at prices ranging from $612.97 to $612.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 9, 2021 at each separate price. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $610.85 | $610.85 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,266 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · derivative · entry 22 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,565 Underlying: Common Stock · 2,000 shares Expires 2026-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,636 | $607.51 | $993,886.36 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,267 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $381.92 | $763,840.00 |
DisclosureSEC source: 0001708138-21-000050 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,950 | $0.00 Strike: $492.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000051 · edgardoc.xml · derivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,950 Underlying: Common Stock · 19,950 shares Expires 2030-12-09 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000051 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,903 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 9, 2022 and 50% on December 9, 2024. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 696 | $654.46 | $455,504.16 |
DisclosureSEC source: 0001708138-20-000091 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,973 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $658.00 | $1,974.00 |
DisclosureSEC source: 0001237899-20-000034 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,669 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.